PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Shilpa Medicare Enters Strategic Partnership with NXI Therapeutics AG

Third major international mandate in recent months reinforces accelerating biotech traction and long-term revenue visibility

 Shilpa Medicare Limited (BSE/NSE: SHILPAMED), a global integrated pharmaceutical and CDMO company, today announced the signing of a long-term development and commercial manufacturing agreement with NXI Therapeutics AG, Switzerland.

Under the terms of agreement, Shilpa group will provide comprehensive CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support. The collaboration spans early development through commercialization, positioning Shilpa as a lifecycle partner for the program.

Autoimmune and immune-modulation segments represents one of the fastest-growing therapeutic categories globally, driven by increasing prevalence and demand for targeted immunotherapies. By securing this mandate at an early stage, Shilpa enhances its participation in high-value, innovation-driven pipelines with scalable commercial potential.

This is the third named partnership deal Shilpa has announced in the past year, as the CDMO continues to expand rapidly amid strengthening demand from Western biotechs for its integrated R&D capabilities and advanced GMP manufacturing. 

While financial terms remain confidential, the agreement includes milestone-linked expansion potential and may evolve into a multi-year commercial supply relationship, subject to successful clinical and regulatory progression.

Mr. Vishnukanth Bhutada, Managing Director, Shilpa Medicare Limited, commented: “This collaboration reinforces Shilpa’s transformation into a strategic innovation partner for global biotech companies. Our integrated development and commercial manufacturing capabilities enable us to support complex assets across the full product lifecycle. We continue to see strong momentum in high-value biologics and specialty therapeutics, strengthening long-term growth visibility for our CDMO platform.”

Dr. Ruben Herrendorff, CEO, NXI Therapeutics AG, added: “Shilpa’s scientific depth, quality systems, and scalable GMP manufacturing capabilities make them an ideal partner as we advance our immunomodulatory program toward clinical and commercial milestones.”

With expanding biologics capabilities, advanced GMP facilities in India, and increasing global biotech engagements, Shilpa continues to strengthen its position as a trusted development and commercial manufacturing partner in high-growth therapeutic segments.

About Shilpa Medicare Limited

Shilpa Medicare Limited is a global pharmaceutical company and integrated CDMO providing end-to-end solutions across small molecules, biologics, and complex therapeutics. The company partners with innovators worldwide to support development through commercialization, with a growing focus on high-value specialty and biologics programs.

About NXI Therapeutics

NXI Therapeutics is a Swiss biotechnology company with a global, long-term perspective, focused on developing the next generation of safe immunotherapies. It aims to truly change the course of autoimmune and alloimmune conditions by realizing powerful targeted immunomodulation that preserves immunocompetence.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026